| Summary: | 碩士 === 國立臺灣大學 === 分子醫學研究所 === 90 === Abstract
Hepatocellular carcinoma (HCC) is a common malignancy with a poor prognosis in Taiwan. Surgery and alcohol local injection are usually applied to treat HCC. However, most of the HCC patients cannot eradicate completely. To eradicate tumors completely and safety, the immunotherapy became more popular. According to the reports, dendritic cell (DC)-based immunotherapy has been applied to treat stage III or IV patients of melanoma, prostate cancer, or renal cell carcinoma. The clinical results have demonstrated that autologous DC-based immunotherapy is safe, and the results are promising. The efficacy of DC-based immunotherapy for HCC has not been well documented. The aim of this study will to investigate whether the DC-based immunotherapy for HCC is safety and effectively in vivo.
In this study, we established a murine HCC model in healthy mice with a normal immune system. Hepa 1-6 cells were subcutaneously inoculated in the flank of C57BL/10J mice to create HCC model. Two courses of DCs were administered weekly. Recorded the tumor size until the grew to 3×3-mm3 (small) or 5×5-mm3 (large) for further in vivo and in vitro study. The results revealed that lymphocytes could be gathered around small HCC after DC-based immunotherapy. Seven of 12 small HCC (58.3%) were completely eradicated, and 4 of 12 small HCC (33.3%) responded to immunotherapy partially which were held in a stable condition for 34.0±7.4 days. For the large HCC, lymphocytes did not gather around the tumors, and the tumors cannot be eradicated effectively by DCs. However, DC-based immunotherapy could slow down the growth rate of large tumors. The result also indicated that it is safety and effectively without autoimmunity disease or liver injury.
The importance of this study is to explore the safety and effectively of DC-based immunotherapy to treat HCC in murine model. Hope it will provide the evidence of human HCC therapy in the future.
|
|---|
